Literature DB >> 30181853

Use of dapagliflozin as an add-on to insulin therapy in patients with suboptimally controlled type 2 diabetes.

Gautam Das1, Ashutosh Surya2, Hussam Abusahmin2.   

Abstract

Entities:  

Year:  2018        PMID： 30181853      PMCID： PMC6116759          DOI： 10.1177/2042018818771434

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN： 2042-0188            Impact factor:   3.565


× No keyword cloud information.
  11 in total

1.  Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Authors:  John P H Wilding; Vincent Woo; Norman G Soler; Andrea Pahor; Jennifer Sugg; Katja Rohwedder; Shamik Parikh
Journal:  Ann Intern Med       Date:  2012-03-20       Impact factor: 25.391

2.  Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.

Authors:  Eiichi Araki; Yukiko Onishi; Michiko Asano; Hyosung Kim; Toshitaka Yajima
Journal:  Diabetes Obes Metab       Date:  2017-02-23       Impact factor: 6.577

3.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

Authors:  Jan Bolinder; Östen Ljunggren; Joel Kullberg; Lars Johansson; John Wilding; Anna Maria Langkilde; Jennifer Sugg; Shamik Parikh
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

4.  Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Authors:  Robert J Heine; Luc F Van Gaal; Don Johns; Michael J Mihm; Mario H Widel; Robert G Brodows
Journal:  Ann Intern Med       Date:  2005-10-18       Impact factor: 25.391

5.  Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.

Authors:  Sunder Mudaliar; Robert R Henry; Guenther Boden; Steven Smith; Alexandros-Georgios Chalamandaris; Dominique Duchesne; Nayyar Iqbal; James List
Journal:  Diabetes Technol Ther       Date:  2013-11-15       Impact factor: 6.118

Review 6.  Insulin-associated weight gain in diabetes--causes, effects and coping strategies.

Authors:  David Russell-Jones; Rehman Khan
Journal:  Diabetes Obes Metab       Date:  2007-11       Impact factor: 6.577

Review 7.  Diabetes: glycaemic control in type 2 (drug treatments).

Authors:  Kees J Gorter; Floris Alexander van de Laar; Paul G H Janssen; Sebastian T Houweling; Guy E H M Rutten
Journal:  BMJ Clin Evid       Date:  2012-10-11

8.  Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Authors:  J P H Wilding; V Woo; K Rohwedder; J Sugg; S Parikh
Journal:  Diabetes Obes Metab       Date:  2013-08-29       Impact factor: 6.577

9.  Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

Authors:  B Komoroski; N Vachharajani; D Boulton; D Kornhauser; M Geraldes; L Li; M Pfister
Journal:  Clin Pharmacol Ther       Date:  2009-01-07       Impact factor: 6.875

Review 10.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112
View more
  1 in total

1.  Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.

Authors:  Ioanna Papakitsou; George Vougiouklakis; Moses S Elisaf; Theodosios D Filippatos
Journal:  Clin Pharmacol       Date:  2019-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.